Modeling Tobacco Regulatory Impacts in Appalachia Using the Experimental Tobacco Marketplace
Launched by MIKHAIL N KOFFARNUS · Jan 22, 2024
Trial Information
Current as of November 12, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This study from the University of Kentucky is designed to understand how proposed rules about tobacco and nicotine products might affect people’s choices and use in Appalachian Kentucky. In a realistic online marketplace, participants will explore and buy tobacco products under different regulatory scenarios and with different nicotine levels (including very low nicotine cigarettes). Researchers will look at overall demand (how much people buy) and which products people switch to when prices or rules change, to see how rural versus more urban areas might respond.
Who can participate and what to expect: Adults aged 21 and older who currently use nicotine or tobacco every day, and who do not plan to quit in the next 9 weeks, may be eligible. The study involves baseline assessments, a 9-week online period where you’ll do shopping tasks in the simulated marketplace and track your tobacco use, plus frequent questionnaires and some biological checks (breath carbon monoxide tests twice daily, saliva cotinine samples). You’ll also report daily use, withdrawal symptoms, and cravings through an app. Participants are randomly assigned to different groups (rural vs peri-urban locations and conventional vs very low nicotine cigarettes) and will experience several regulatory scenarios during the study. The trial is currently enrolling and results aren’t available yet; the estimated study completion date is 2028.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • At least 21 years old
- • Consume nicotine and/or tobacco products daily
- • Have no plans to quit nicotine/tobacco consumption or seek treatment in the subsequent 9 weeks
- • Read and understand English
- Exclusion Criteria:
About Mikhail N Koffarnus
Mikhail N. Koffarnus is a dedicated clinical trial sponsor focused on advancing medical research and improving patient outcomes through innovative therapeutic interventions. With a strong background in clinical pharmacology and a commitment to rigorous scientific methodology, Koffarnus leads and oversees a diverse portfolio of clinical trials. His expertise encompasses the design, implementation, and management of studies that explore novel treatment options across various therapeutic areas. By fostering collaboration among multidisciplinary teams and prioritizing ethical standards, Mikhail N. Koffarnus aims to contribute significantly to the advancement of healthcare and the discovery of effective medical solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lexington, Kentucky, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported